ARVO Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marcus, D.
Right arrow Articles by Fine, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Marcus, D.
Right arrow Articles by Fine, S.
Invest Ophthalmol Vis Sci 2002;43: E-Abstract 1207.
© 2002 ARVO

The Age-related Macular Degeneration Radiotherapy Trial (AMDRT): Baseline Characteristics

DM Marcus1, MG Maguire2, AM Maguire2 and SL Fine2AMDRT Study Group

1 Departments of Ophthalmology Medical College of Georgia Augusta GA
2 Scheie Eye Institute University of Pennsylvania Philadelphia PA

Commercial Relationships:  D.M. Marcus, None; M.G. Maguire, None; A.M. Maguire, None; S.L. Fine, None.
Grant Identification: Research to Prevent Blindness

Abstract

Purpose: To describe the baseline characteristics of eyes enrolled in the AMDRT.
Methods: Eleven centers enrolled 89 patients in the AMDRT, a randomized clinical pilot trial assessing the efficacy of external beam irradiation (5 x 4 Gy fractions=20Gy; 6 MeV) versus observation in the treatment of new and recurrent subfoveal choroidal neovascularization (CNV) in AMD. Eligibility criteria include visual acuity 20/320 and CNV not amenable to MPS laser treatment or photodynamic therapy with verteporfin. Primary outcome measures are change in visual acuity. Secondary outcome measures are fluorescein angiographic response and incidence of side effects.
Results: Eighty patients demonstrate new CNV and 9 patients demonstrate recurrent CNV. At baseline, the radiation and observation groups are not different with respect to age (mean 77), gender (57% males and 63% females), race (100% caucasian), and hypertensive status. Baseline visual acutiy is not different (p<0.33) between the groups (45%20/80). Flourescein angiographic features are not different between the groups (85% minimally classic or occult CNV; 71% comprised of 25% blood; 80% comprised of <25% fibrosis).
Conclusion: The AMDRT will determine if trends exist for a beneficial radiotherapy effect at a dose of 5 x 4 Gy.

Keywords: 308 age-related macular degeneration • 357 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 538 radiation therapy

© 2002, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. For permission to reproduce any part of this abstract, contact the ARVO Office at arvo{at}arvo.org.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH